Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation  

作　　者：卓亚琪 ZHUO Yaqi(Dept Hematol,Zhujiang Hosp,South Med Univ,Guangzhou 510280)

机构地区：[1]Dept Hematol,Zhujiang Hosp,South Med Univ,Guangzhou 510280

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第2期123-123,共1页中国医学文摘（内科学分册（英文版）

摘　　要：Objective To investigate the safety and efficacy of donor-derived CD19+or sequential CD19+CD22+chimeric antigen receptor T-cell(CAR-T)therapy in patients with B-cell acute lymphoblastic leukemia(BALL)afterallogeneic hematopoieticstem cell transplantation(allo-HSCT).Methods The data of 22 patients with B-ALL who relapsed after allo-HSCT and underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed.The primary endpointwasoverall survival(OS),and the secondary endpoints wereeevent-free survival(EFS),complete remission(CR)rate,and Grade 3-4 adverse events.Results A total of 81.82%(n=18)of the 22 patients achieved minimal residual disease-negative CR after CAR-T infusion.The median follow-up time was 1037(95%CI 546-1509)days,and the median OS and EFS were 287(95%CI 132-441)days and 212(95%CI 120-303)days,respectively.The 6-month 0S and EFS rates were 67.90%(95%CI 48.30%-84.50%)and 58.70%(95%CI 37.92%-79.48%),respectively。

关 键 词：PATIENTS HEMATOPOIETIC LYMPHOBLASTIC 

分 类 号：R733.71[医药卫生—肿瘤]